Inventor · disambiguated record
Christopher De Savi
Also filed as: DE SAVI CHRISTOPHER
9 granted patents·6 pending applications·8 citations·filing 2009–2024
81Inventor score
Top patents by PatentIndex Score
15 records- 0193US11718602B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Aug 8, 2023·2 cites·8 claims
- 0280US9155727B2Chemical compoundsASTRAZENECA AB·Filed 2014·Granted Oct 13, 2015·5 cites·11 claims
- 0380US2025289801A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Application pending·0 cites
- 0474US9845331B2Chemical compoundsASTRAZENECA AB·Filed 2016·Granted Dec 19, 2017·1 cites·8 claims
- 0573US2022340592A1Chemical compoundsASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 0672US12172983B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2021·Granted Dec 24, 2024·0 cites·21 claims
- 0768US11352369B2Pyridine and pyrimidine derivativesASTRAZENECA AB·Filed 2020·Granted Jun 7, 2022·0 cites·19 claims
- 0861US10717746B2Chemical compoundsASTRAZENECA AB·Filed 2017·Granted Jul 21, 2020·0 cites·6 claims
- 0960US2024382483A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 1058US2024299387A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 1158US2024308981A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 1257US10130617B2Chemical compoundsASTRAZENECA AB·Filed 2017·Granted Nov 20, 2018·0 cites·13 claims
- 1356US2019038607A1Chemical compoundsASTRAZENECA AB·Filed 2018·Application pending·0 cites
- 1454US9616050B2Chemical compoundsASTRAZENECA AB·Filed 2015·Granted Apr 11, 2017·0 cites·8 claims
- 1540US8273774B2Phenoxypyridinylamide compoundsANDREWS GLEN·Filed 2009·Granted Sep 25, 2012·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Christopher De Savi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →